The Use of Ceftazidime-Avibactam in a Pediatric Intensive Care Unit-An Observational Prospective Study

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Nov 27

PMID 39596732

Authors

Raquel Garcia Romero

Elena Fresan-Ruiz

Carmina Guitart

Sara Bobillo-Perez

Iolanda Jordan

Affiliations

Soon will be listed here.

Abstract

Infections caused by carbapenem-resistant Enterobacterales (CRE) are progressively increasing in Pediatric Intensive Care Units (PICUs). Its treatment is challenging due to the lack of pediatric trials. CRE infections are associated with significantly poor outcomes, but ceftazidime-avibactam (CAZ-AVI) has been reported to be successful in their treatment. This study aimed to describe the use and outcome of CAZ-AVI in a PICU. Ten patients were included, with 12 episodes of clinical suspicion or confirmed multidrug-resistant (MDR) bacterial infections treated with CAZ-AVI for surgical prophylaxis, suspicion of sepsis, pneumonia, and surgical wound infection. Of these patients, 80% received empirical treatment because of previous MDR bacterial colonization, and 60% were administrated combination therapy with aztreonam for Metallo-β-Lactamases (MBL)strains. No bacteria were resistant to CAZ-AVI. The average duration of the treatment was 3 days when cultures turned negative and 7 days when MDR bacteria were isolated. This was an observational prospective study of children treated with CAZ-AVI in the PICU of a tertiary hospital in 2022. Epidemiological, clinical, microbiological, and outcome data were collected. The most frequent use of CAZ-AVI in our PICU was the short-term empirical treatment for patients with previous MDR bacterial colonization and clinical suspicion of bacteremia or sepsis. Furthermore, the combination of CAZ-AVI plus aztreonam could be more effective for CRE infections, especially type Ambler class B as MBL strains.

References

Franzese R, McFadyen L, Watson K, Riccobene T, Carrothers T, Vourvahis M . Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. Clin Pharmacol Ther. 2021; 111(3):635-645. PMC: 9298731. DOI: 10.1002/cpt.2460. View

Jajoo M, Manchanda V, Chaurasia S, Sankar M, Gautam H, Agarwal R . Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India. PLoS One. 2018; 13(6):e0180705. PMC: 6023165. DOI: 10.1371/journal.pone.0180705. View

Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M . Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis. 2021; 73(9):1664-1676. DOI: 10.1093/cid/ciab176. View

Bradley J, Roilides E, Broadhurst H, Cheng K, Huang L, MasCasullo V . Safety and Efficacy of Ceftazidime-Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. Pediatr Infect Dis J. 2019; 38(9):920-928. DOI: 10.1097/INF.0000000000002395. View

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

Bradley J, Byington C, Shah S, Alverson B, Carter E, Harrison C . The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011; 53(7):e25-76. PMC: 7107838. DOI: 10.1093/cid/cir531. View

Chiotos K, Hayes M, Gerber J, Tamma P . Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. J Pediatric Infect Dis Soc. 2019; 9(1):56-66. PMC: 7047006. DOI: 10.1093/jpids/piz085. View

Fiore M, Alfieri A, Di Franco S, Pace M, Simeon V, Ingoglia G . Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics (Basel). 2020; 9(7). PMC: 7400227. DOI: 10.3390/antibiotics9070388. View

Bone R, Sprung C, Sibbald W . Definitions for sepsis and organ failure. Crit Care Med. 1992; 20(6):724-6. DOI: 10.1097/00003246-199206000-00002. View

10.

Little M, Qin X, Zerr D, Weissman S . Molecular diversity in mechanisms of carbapenem resistance in paediatric Enterobacteriaceae. Int J Antimicrob Agents. 2011; 39(1):52-7. PMC: 3237943. DOI: 10.1016/j.ijantimicag.2011.09.014. View

11.

Chiotos K, Tamma P, Flett K, Karandikar M, Nemati K, Bilker W . Increased 30-Day Mortality Associated With Carbapenem-Resistant Enterobacteriaceae in Children. Open Forum Infect Dis. 2018; 5(10):ofy222. PMC: 6186173. DOI: 10.1093/ofid/ofy222. View

12.

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

13.

Logan L, Bonomo R . Metallo-β-Lactamase (MBL)-Producing Enterobacteriaceae in United States Children. Open Forum Infect Dis. 2016; 3(2):ofw090. PMC: 4943557. DOI: 10.1093/ofid/ofw090. View

14.

Pannaraj P, Bard J, Cerini C, Weissman S . Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. Pediatr Infect Dis J. 2014; 34(1):11-6. PMC: 4437704. DOI: 10.1097/INF.0000000000000471. View

15.

Folgori L, Bielicki J . Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance. J Pediatr Intensive Care. 2019; 8(1):17-24. PMC: 6506670. DOI: 10.1055/s-0038-1677535. View

16.

Nour I, Eldegla H, Nasef N, Shouman B, Abdel-Hady H, Shabaan A . Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit. J Hosp Infect. 2017; 97(1):52-58. DOI: 10.1016/j.jhin.2017.05.025. View

17.

Logan L, Renschler J, Gandra S, Weinstein R, Laxminarayan R . Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999-2012. Emerg Infect Dis. 2015; 21(11):2014-21. PMC: 4622248. DOI: 10.3201/eid2111.150548. View

18.

Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M . British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011; 66 Suppl 2:ii1-23. DOI: 10.1136/thoraxjnl-2011-200598. View

19.

Asokan G, Ramadhan T, Ahmed E, Sanad H . WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Med J. 2019; 34(3):184-193. PMC: 6505350. DOI: 10.5001/omj.2019.37. View

20.

Berrios-Torres S, Umscheid C, Bratzler D, Leas B, Stone E, Kelz R . Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017; 152(8):784-791. DOI: 10.1001/jamasurg.2017.0904. View